Moreover, high expression of these 2 KIF members was significantly associated with advanced clinical stage (OR = 1.98, 95% CI: 1.57–2.50, P < .001; OR = 2.63, 95% CI: 2.03–3.41, P < .001, respectively), positive lymph node metastasis (OR = 2.32, 95% CI: 1.65–3.27, P < .001; OR = 2.13, 95% CI: 1.59–2.83, P < .001, respectively), and distant metastasis (OR = 2.20, 95% CI: 1.21–3.99, P = .010; OR = 5.25, 95% CI: 2.82–9.77, P < .001, respectively); only high KIF20A expression was related to poor differentiation grade (OR = 1.82, 95% CI: 1.09–3.07, P = .023). The gene discussed is KIF20A; the disease is metastatic malignant neoplasm in the lymph nodes.